{"id":"https://genegraph.clinicalgenome.org/r/d07466b3-be1e-4603-8536-143edf824029v1.0","type":"EvidenceStrengthAssertion","dc:description":"***ALG2*** was first reported in relation to autosomal recessive Congenital Disorders of Glycosylation by Thiel C, et al., 2003 (PMID: 12684507). At least 6 unique variants (varied in missense,frameshift, indels) have been reported in humans. Evidence supporting this gene-disease relationship includes both case-level data and experimental data. Variants in this gene have been reported in at least 5 probands from publications (PMIDs: 12684507, 34980536, 23404334, 30397276, 33644825). Patient have a range of range of symptoms, such as developmental delay, seizures, poor vision, coagulopathy, and delayed myelinization. Patients may also present with congenital myasthenic syndromes (CMS) which characterized by fatigable muscle weakness. The disease mechanism appears to be biallelic loss of function. Heterozygous carriers are reportedly unaffected. This gene-disease relationship is supported by the biochemical function of *ALG2*, which encodes an alpha-1,3-mannosyltransferase that catalyzes the second and third mannosylation steps in the N-linked glycosylation pathway (PMID:  23404334). A yeast assay was done where cDNAs encoding wild type hALG2 or the Δ1040G mutant were introduced into the temperature-sensitive alg2-1 yeast strain.This showed that only the wild-type hALG2 cDNA, not the mutant Δ1040G form, restored the formation of lipid-linked oligosaccharides in alg2-1 cells (PMID: 12684507) In addition, an *ALG2 *mutant medaka model was employed to explore the effects of *ALG2 *gene mutations on embryonic development. The investigation revealed that introduced mutations in the *ALG2* gene resulted in abnormalities during late-stage embryonic development, reminiscent of the multisystemic phenotypes observed in *ALG2*-CDG patients. \nIn that same model there was rescue of the phenotype with the injection of either medaka or human alg2 mRNA, the survival of homozygous mutant embryos was restored (PMID: 34106226). In summary, there is strong evidence to support this gene-disease relationship. Although more evidence, genetic and experimental, is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. A classification of STRONG was approved by the ClinGen Congenital Disorders of Glycosylation GCEP on 11/15/23 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/d07466b3-be1e-4603-8536-143edf824029","GCISnapshot":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc","calculatedEvidenceStrength":"Strong","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2023-12-21T14:14:12.774Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10135","date":"2023-11-15T17:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d7d1b890-192d-4974-90d6-9b2307238bc7_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24461433","rdfs:label":"F1 - Bedouin family","estimatedLodScore":1.45,"family":{"id":"https://genegraph.clinicalgenome.org/r/d7d1b890-192d-4974-90d6-9b2307238bc7","type":"Family","rdfs:label":"F1 - Bedouin family"},"meetsInclusionCriteria":true,"phenotypeFreeText":" Trendelenburg gait, Jitter;  Carbohydrate deficient transferrin (CDT) was normal in one individual and only marginally elevated in two others ","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0002938","obo:HP_0003325","obo:HP_0007340","obo:HP_0004302"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d9ac9aff-9841-4ea9-8125-138b8ee8dc47"},"publishedLodScore":3.5,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/f3cc5952-8e35-42a4-8b2a-6435e03bae10_proband_segregation","type":"FamilyCosegregation","dc:description":"Case 5 had WES done ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23404334","rdfs:label":"Family 2 - Cases 3-6","estimatedLodScore":2.06,"family":{"id":"https://genegraph.clinicalgenome.org/r/f3cc5952-8e35-42a4-8b2a-6435e03bae10","type":"Family","rdfs:label":"Family 2 - Cases 3-6"},"meetsInclusionCriteria":true,"phenotypeFreeText":"Mild learning difficulties, proximal joint contractures, Mild facial weakness (no ptosis or ocular issues).\n\nMild respiratory insufficiency (in Cases 3 and 4","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0003701","obo:HP_0002333","obo:HP_0001270","obo:HP_0001763","obo:HP_0020152","obo:HP_0000218","obo:HP_0003473","obo:HP_0001252","obo:HP_0001284"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b80f7b94-5070-4492-ae92-f999156fa71f"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":2.1},{"id":"https://genegraph.clinicalgenome.org/r/5d1ae9e4-fdc4-4ab5-b2ce-d9a8568ffa75_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23067995-c9b0-4284-a66b-a863bebe0b70","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23067995-c9b0-4284-a66b-a863bebe0b70_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33644825","allele":{"id":"https://genegraph.clinicalgenome.org/r/19458fcc-5c0a-47b2-93cd-b23939cf755b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_033087.4(ALG2):c.752G>T (p.Arg251Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA374227940"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/5d1ae9e4-fdc4-4ab5-b2ce-d9a8568ffa75","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33644825","rdfs:label":"AR07","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":{"id":"https://genegraph.clinicalgenome.org/r/19458fcc-5c0a-47b2-93cd-b23939cf755b"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Bilateral fronto-parietal atrophy, cochlear and retrocochlear hearing loss","phenotypes":["obo:HP_0001263","obo:HP_0003642","obo:HP_0000407","obo:HP_0000431","obo:HP_0001249","obo:HP_0033725","obo:HP_0000252","obo:HP_0004322","obo:HP_0000821","obo:HP_0012368","obo:HP_0006829","obo:HP_0002014","obo:HP_0011097","obo:HP_0000369","obo:HP_0000218","obo:HP_0003186","obo:HP_0000817"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/23067995-c9b0-4284-a66b-a863bebe0b70_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/5be2613a-9d39-4d44-b302-3bc13d371bb6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee92e82e-aa8c-4ee1-8f9c-8e458306796e","type":"EvidenceLine","dc:description":"consanguineous parents","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ee92e82e-aa8c-4ee1-8f9c-8e458306796e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Transfection of HEK 293 cells with wild-type and mutant ALG2 complementary DNA showed reduction in ALG2 expression to approximately 20% of control levels in Western blot analysis of cell lysates.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ee92e82e-aa8c-4ee1-8f9c-8e458306796e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23404334","allele":{"id":"https://genegraph.clinicalgenome.org/r/12a86a92-88b3-4c89-ad82-c6cb5c9e039e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_033087.4(ALG2):c.203T>G (p.Val68Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA185983"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5be2613a-9d39-4d44-b302-3bc13d371bb6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23404334","rdfs:label":"Case 7","ageType":"AgeAtReport","ageUnit":"Years","ageValue":59,"allele":{"id":"https://genegraph.clinicalgenome.org/r/12a86a92-88b3-4c89-ad82-c6cb5c9e039e"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Facial and neck muscles are strong\n\nElectromyography findings: Significant decrement in compound muscle action potentials and marked abnormalities in single-fiber electromyography.\n\nMuscle biopsy (at age 50): Tubular aggregates in type II fibers and non-specific myopathic features","phenotypes":["obo:HP_0003701","obo:HP_0002515","obo:HP_0002527","obo:HP_0003691","obo:HP_0008959","obo:HP_0002938","obo:HP_0003473"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ee92e82e-aa8c-4ee1-8f9c-8e458306796e_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b35e416a-bb66-4961-83d0-0029d0f2ffbd_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/193569c5-bc2b-4035-9336-4a7335dfcc11","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/193569c5-bc2b-4035-9336-4a7335dfcc11_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Western blot on cell lysates from HEK293 cells transfected with the frameshift variant p.Gly347Valfs*27, where the protein band isn't distinctly visible. Suggesting potential instability of the truncated protein, nonsense medicated decay would not be expected. \n\nYeast Assay from PMID:12684507","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/193569c5-bc2b-4035-9336-4a7335dfcc11_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34980536","allele":{"id":"https://genegraph.clinicalgenome.org/r/dabbec72-e2ae-416a-b21d-84286418d345","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_033087.4(ALG2):c.1040del (p.Gly347ValfsTer27)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252406"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/5d7d2fcc-fe54-4f8a-bf0a-4724d68daded","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5d7d2fcc-fe54-4f8a-bf0a-4724d68daded_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"HEK293 cells transfected with the missense mutation p.Gly80Asp exhibited significantly reduced expression. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5d7d2fcc-fe54-4f8a-bf0a-4724d68daded_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34980536","allele":{"id":"https://genegraph.clinicalgenome.org/r/4bc32957-c868-4c5d-8f61-ed59a045e143","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_033087.4(ALG2):c.239G>A (p.Gly80Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5156435"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/b35e416a-bb66-4961-83d0-0029d0f2ffbd","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34980536","rdfs:label":"Female - Case Report","allele":[{"id":"https://genegraph.clinicalgenome.org/r/dabbec72-e2ae-416a-b21d-84286418d345"},{"id":"https://genegraph.clinicalgenome.org/r/4bc32957-c868-4c5d-8f61-ed59a045e143"}],"firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":" absence of Moro reflex (most likely due to muscle weakness) and tendon reflexes as well as weak grip reflexes in both hands and feet.  Suction reflex was also absent \n\nNegative genetic testing for spinal muscular atrophy.","phenotypes":["obo:HP_0001776","obo:HP_0001252","obo:HP_0003701","obo:HP_0030205","obo:HP_0001601","obo:HP_0011968"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/5d7d2fcc-fe54-4f8a-bf0a-4724d68daded_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/193569c5-bc2b-4035-9336-4a7335dfcc11_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/d9ac9aff-9841-4ea9-8125-138b8ee8dc47_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/40ed4beb-0495-4b5f-bb5a-271258f89b66_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18977a17-4945-4068-b597-9d6c8331d210","type":"EvidenceLine","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18977a17-4945-4068-b597-9d6c8331d210_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12684507","allele":{"id":"https://genegraph.clinicalgenome.org/r/600b0c40-4f21-4586-9c42-305a42497818","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_033087.4(ALG2):c.393G>T (p.Lys131Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252407"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/5524cac9-57ba-47ac-bffa-01f26b293721","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5524cac9-57ba-47ac-bffa-01f26b293721_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Researchers introduced the cDNAs encoding wild-type hALG2 or the Δ1040G mutant into the temperature-sensitive alg2-1 yeast strain. This showed that only the wild-type hALG2 cDNA, not the mutant Δ1040G, restored the formation of lipid-linked oligosaccharides in alg2-1 cells.\n \nTransfection of frameshift variant in HEK293 cells. Western blot was done on cell lysates showing a protein band was not visible. PMID: 34980536\n","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5524cac9-57ba-47ac-bffa-01f26b293721_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12684507","allele":{"id":"https://genegraph.clinicalgenome.org/r/dabbec72-e2ae-416a-b21d-84286418d345"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/40ed4beb-0495-4b5f-bb5a-271258f89b66","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12684507","rdfs:label":"M.S","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/dabbec72-e2ae-416a-b21d-84286418d345"},{"id":"https://genegraph.clinicalgenome.org/r/600b0c40-4f21-4586-9c42-305a42497818"}],"firstTestingMethod":"PCR","phenotypeFreeText":"accumulation of the short dolichol-linked oligosaccharides Man1GlcNAc2-PP-dolichol and Man2GlcNAc2-PP-dolichol","phenotypes":["obo:HP_0001929","obo:HP_0001263","obo:HP_0000612","obo:HP_0000518","obo:HP_0003642","obo:HP_0034295","obo:HP_0001250","obo:HP_0001348","obo:HP_0003645","obo:HP_0012448"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/5524cac9-57ba-47ac-bffa-01f26b293721_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/18977a17-4945-4068-b597-9d6c8331d210_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.1},{"id":"https://genegraph.clinicalgenome.org/r/b80f7b94-5070-4492-ae92-f999156fa71f_proband_score_evidence_line","type":"EvidenceLine","direction":"Inconclusive","specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/b013060a-2c78-4de9-a38d-2e81165b96d3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf92509d-0d5e-40f2-8e51-6fec47ab7015","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf92509d-0d5e-40f2-8e51-6fec47ab7015_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30397276","allele":{"id":"https://genegraph.clinicalgenome.org/r/19458fcc-5c0a-47b2-93cd-b23939cf755b"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/b013060a-2c78-4de9-a38d-2e81165b96d3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30397276","rdfs:label":"AR05","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"allele":{"id":"https://genegraph.clinicalgenome.org/r/19458fcc-5c0a-47b2-93cd-b23939cf755b"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":" refractory epilepsy, developmental disability, mongoloid palpebral fissures, bilateral epicanthus","phenotypes":["obo:HP_0000431","obo:HP_0001249","obo:HP_0000252","obo:HP_0020045","obo:HP_0003642","obo:HP_0000518","obo:HP_0000612"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/cf92509d-0d5e-40f2-8e51-6fec47ab7015_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":7.6},{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e27ff688-c6f2-4a2b-99d3-e6c256bffdb9","type":"EvidenceLine","dc:description":"Not a mouse model ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/954d0af1-c548-49c6-8ee2-3f14111e6e36","type":"Finding","dc:description":"Without mRNA injection, homozygous alg2p.G336*/p.G336* mutants were absent. With the injection of either medaka or human alg2 mRNA, the survival of homozygous mutant embryos was restored. The injected mRNA also efficiently rescued the gross morphology phenotype and extended the lifespan by at least 16 days.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34106226","rdfs:label":"Rescue of alg2p.G336*/p.G336* medaka mutants ","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e108c9f0-ec74-48c9-9b15-12e0b213cf39","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d4282c4-8019-4e45-a2cb-5b2979b1f798","type":"Finding","dc:description":"Transduction of the Δ1040G mutant had no impact (Figure 9, lane 5). ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12684507","rdfs:label":"Rescue of M.S cells ","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7cf0a844-8272-4529-92e0-f6721b50c411","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2d4bbae8-86f1-43f8-92a2-1882a5105d4e","type":"FunctionalAlteration","dc:description":"The medaka embryos with the introduced mutations displayed normal early embryonic development, but abnormalities became apparent just prior to hatching. The mutants exhibited multisystemic phenotypes similar to those observed in ALG2-CDG patients. \nComparing the N-glycan fingerprints of wild-type Alg2 medaka with the Alg2:p.G366* N-glycan fingerprints revealed severe hypo-N-glycosylation. There was a reduction in the levels of complex-type (48% less) and high-mannose-type (54% less) N-glycans. Both the human ALG2:p.G347Vfs26 protein (from the ALG2 index patient) and the medaka mutants expressing the Alg2:p.G336 protein exhibited prominent hypo-N-glycosylation.\n\n\"Note in the mutant craniofacial defects, including prominently shortened snout (bracket), persistent yolk sac (y), non-inflated swim bladder (sb), enlarged liver (unfilled arrowhead), secondary tubular heart (black arrowhead) and clogging of blood, slightly smaller eyes (e).\"","dc:source":"https://pubmed.ncbi.nlm.nih.gov/34106226","rdfs:label":"Medaka alg2 variants "}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/f7cb8bd0-58b2-4644-a041-76f42f564fbc_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3dc25742-1015-41c1-bf2a-476fce3cabc7","type":"EvidenceLine","dc:description":"upscored because ALG2 function in N-glycosylation pathway is well explained","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9c9103e2-e5cd-4831-921d-006493ef84c7","type":"Finding","dc:description":"Mutations in this pathway are labeled as Congenital disorders of glycosylation type Ii. Congenital disorder of glycosylation type Ii (CDG1I) is a rare autosomal recessive disorder characterized by neurologic involvement, including a convulsive syndrome of unknown origin, axial hypotonia, and mental and motor regression.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12684507","rdfs:label":"Thiel et al. Biochemical Function of ALG2","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5}],"evidenceStrength":"Strong","sequence":7297,"specifiedBy":"GeneValidityCriteria9","strengthScore":12.1,"subject":{"id":"https://genegraph.clinicalgenome.org/r/WJTu_jEIQ6Y","type":"GeneValidityProposition","disease":"obo:MONDO_0011933","gene":"hgnc:23159","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_f7cb8bd0-58b2-4644-a041-76f42f564fbc-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}